Cortexin
- Category
- Brain & Cognition
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
What it is
A cerebral-cortex polypeptide complex marketed for cognitive support and stroke recovery. Human evidence is moderate at best, mostly older Eastern European trials on stroke recovery and elderly cognition, while pediatric and developmental-delay uses rest on low-confidence data. As a crude tissue extract, it carries a real allergic-reaction risk and a theoretical seizure concern. It is not FDA-approved and is sold as an unregulated research-grade product.
Read Full recordStudied uses & evidence
Studied uses(5)
Neuroprotection in acute and chronic brain ischemia
MediumSupported by two Russian human RCTs and animal studies; not independently replicated outside Russia.
Neurotropic effects in developmental delay models
LowSingle animal study in developmental-delay models; no human confirmation yet.
Cognitive improvement in elderly patients
MediumOne human RCT in elderly patients, plus uncontrolled studies; not independently replicated.
Evidence limits
- Evidence Level
- Moderate Evidence (registered drug in Russia with published studies)
Cortexin is a registered pharmaceutical in Russia with more extensive clinical evidence than typical bioregulators. PMC-indexed studies demonstrate neuroprotective activity comparable to Cerebrolysin in animal models. Russian clinical trials have enrolled hundreds of patients for conditions including stroke, TBI, epilepsy, and cognitive impairment. However, most studies are Russian-origin, and the drug has not undergone FDA or EMA review. Independent Western replication is limited.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNot recommended for children outside the pediatric indications on the Russian label; not approved in the US.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Risk summary(3)
Risks = level of concern: High · Moderate · Low · Theoretical
Injection site reactions
LowAllergic reactions
HighSeizure threshold effects
Theoretical
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.